Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
Background Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors. We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apat...
Saved in:
| Main Authors: | Lin Li, Rong Huang, Huizi Sha, Baorui Liu, Zhengyun Zou, Guiying Zhang, Yu Ren, Fufeng Wang, Jiayu Wang, Lianjun Zhao, Kelin Zheng, Mengke Zhao, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Rui Mei, Yitao Wang, You Tian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/6/e008611.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01) -
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01) -
Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01) -
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
by: Yakun Wang, et al.
Published: (2025-03-01) -
The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)